Contact
searchSearch
HMP Global

News

News
Neuropsychiatric Symptoms are Central and Treatable in Alzheimer Disease Care
12/17/2025
Lisa Kuhns, PhD, MD
Neuropsychiatric symptoms in Alzheimer disease are now widely viewed as core, treatable features of dementia rather than side effects, and experts say the field is shifting toward earlier recognition and more person-centered care, according...
Neuropsychiatric symptoms in Alzheimer disease are now widely viewed as core, treatable features of dementia rather than side effects, and experts say the field is shifting toward earlier recognition and more person-centered care, according...
Neuropsychiatric symptoms in...
12/17/2025
Annals of Long-Term Care
News
Fine Particulate Air Pollution Linked to Greater Alzheimer Neuropathology, Study Finds
12/16/2025
Grace Taylor, MS, MA
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA Neurology links higher exposure to fine particulate air pollution (PM2.5) with more severe Alzheimer-related brain changes and faster cognitive decline in older adults.
Research published in JAMA...
12/16/2025
Annals of Long-Term Care
News
Agitation Monitoring in Alzheimer Disease: Passive Sensing Shows Early but Limited Promise
12/11/2025
Juliet Gallagher
A recent study highlights the expanding role of passive sensing technologies to assess subjective experiences—including agitation, sadness, and anhedonia—in persons living with Alzheimer disease and related dementias (AD/ADRD). As traditional...
A recent study highlights the expanding role of passive sensing technologies to assess subjective experiences—including agitation, sadness, and anhedonia—in persons living with Alzheimer disease and related dementias (AD/ADRD). As traditional...
A recent study highlights the...
12/11/2025
Annals of Long-Term Care
News
Updated Early Alzheimer Care Pathway Aims to Improve Timely Diagnosis and Treatment in the US
12/04/2025
Hannah Musick
A new Early Alzheimer’s Disease Patient Care Pathway outlines scalable, system-wide strategies to improve timely diagnosis, integrate emerging biomarkers and anti-amyloid therapies, and streamline care coordination across US health systems.
A new Early Alzheimer’s Disease Patient Care Pathway outlines scalable, system-wide strategies to improve timely diagnosis, integrate emerging biomarkers and anti-amyloid therapies, and streamline care coordination across US health systems.
A new Early Alzheimer’s Disease...
12/04/2025
Annals of Long-Term Care
News
Gabapentin Enacarbil Lowers Nighttime Agitation in Dementia Patients With Restless Legs Syndrome
11/26/2025
Grace Taylor, MS, MA
A randomized trial shows that treating restless legs syndrome with gabapentin enacarbil can significantly reduce nighttime agitation and improve sleep in older adults with Alzheimer disease–related dementia.
A randomized trial shows that treating restless legs syndrome with gabapentin enacarbil can significantly reduce nighttime agitation and improve sleep in older adults with Alzheimer disease–related dementia.
A randomized trial shows that...
11/26/2025
Annals of Long-Term Care
News
Widespread Misunderstanding of Agitation in Alzheimer Dementia Leaves US Caregivers Struggling
11/20/2025
Grace Taylor, MS, MA
A national survey reveals that widespread misunderstanding of agitation in Alzheimer dementia is leaving millions of US caregivers emotionally drained, isolated, and struggling without adequate clinical support.
A national survey reveals that widespread misunderstanding of agitation in Alzheimer dementia is leaving millions of US caregivers emotionally drained, isolated, and struggling without adequate clinical support.
A national survey reveals that...
11/20/2025
Annals of Long-Term Care
News
Medical Cannabis Certifications for Alzheimer Disease Agitation Decline in Recreational States
11/10/2025
Juliet Gallagher
A 2024–2025 review of U.S. state medical cannabis programs found that Alzheimer disease (AD) and agitation associated with dementia remain qualifying conditions in 19 of 38 states. Despite this widespread policy inclusion, AD-related...
A 2024–2025 review of U.S. state medical cannabis programs found that Alzheimer disease (AD) and agitation associated with dementia remain qualifying conditions in 19 of 38 states. Despite this widespread policy inclusion, AD-related...
A 2024–2025 review of U.S. state...
11/10/2025
Annals of Long-Term Care
News
Agitated Behaviors in Alzheimer Disease Strongly Linked to Caregiver Burden in US Survey
11/07/2025
Hannah Musick
A US caregiver survey found that nearly all individuals with Alzheimer disease exhibit agitated behaviors, which are strongly linked to increased caregiver burden, anxiety, depression, and reduced work productivity.
A US caregiver survey found that nearly all individuals with Alzheimer disease exhibit agitated behaviors, which are strongly linked to increased caregiver burden, anxiety, depression, and reduced work productivity.
A US caregiver survey found that...
11/07/2025
Annals of Long-Term Care
News
Agitated Behaviors in Alzheimer Disease Strongly Linked to Caregiver Burden in US Survey
11/07/2025
Hannah Musick
A US caregiver survey found that nearly all individuals with Alzheimer disease exhibit agitated behaviors, which are strongly linked to increased caregiver burden, anxiety, depression, and reduced work productivity.
A US caregiver survey found that nearly all individuals with Alzheimer disease exhibit agitated behaviors, which are strongly linked to increased caregiver burden, anxiety, depression, and reduced work productivity.
A US caregiver survey found that...
11/07/2025
Annals of Long-Term Care
News
Brexpiprazole Shows Consistent Efficacy Across Subgroups in Alzheimer-Related Agitation
10/30/2025
Grace Taylor, MS, MA
A pooled analysis finds that 2 or 3 mg/day of brexpiprazole consistently reduces agitation symptoms across nearly all subgroups of patients with Alzheimer dementia.
A pooled analysis finds that 2 or 3 mg/day of brexpiprazole consistently reduces agitation symptoms across nearly all subgroups of patients with Alzheimer dementia.
A pooled analysis finds that 2...
10/30/2025
Annals of Long-Term Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use